Trials / Unknown
UnknownNCT02580617
A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease
A Phase 1 Clinical Study to Evaluate the Safety of Allogeneic Adipose-derived Stem Cells in the Subjects With Crohn's Disease
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Anterogen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I study to evaluate the safety of ALLO-ASC-CD for the treatment of crohn' disease. ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells.
Detailed description
Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore, their immunomodulatory effects are significant for treating immune-related diseases, such as crohn's disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ALLO-ASC | Infusion for Crohn's disease |
Timeline
- Start date
- 2015-11-09
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2015-10-20
- Last updated
- 2023-08-25
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02580617. Inclusion in this directory is not an endorsement.